Keyu Chen

Keyu Chen

Auto-generated profile, based on publicly available information

Keyu Chen

The First Hospital of Jiaxing & The Affiliated Hospital of Jiaxing University Jiaxing China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2023 in Cancer Medicine
Verified
Journal Article
Open access
KCKeyu Chen
Keyu Chen
JXJiaojiao Xu
Jiaojiao Xu
WWWei Wang
Wei Wang
RJRuiyuan Jiang
Ruiyuan Jiang
HZHuanping Zhang
Huanping Zhang
MFMeiyu Fang
Meiyu Fang
Purpose: Phyllodes tumors (PTs) are rare neoplasms with a certain risk of recurrence and/or metastasis. In clinical practice, there is a lack of high‐quality clinical studies and unified guidelines to guide the treatment.Materials and Methods: All malignant and recurrence/metastasis PTs were retrospectively collected, which were diagnosed from 2008 to 2022.Results: A total of 82 patients were enrolled, including 69 malignant and 13 borderline tumors. 96.3% (79/82) received surgical treatment. During a median follow‐up of 55.5 months, 20 patients (20/82, 24.4%) had distant metastasis (DM), while 32 (32/82, 39.0%) had local recurrence (LR). Univariate analysis showed the survival of PTs was associated with surgical methods (p < 0.001), tumor size (p = 0.026), and biological behavior (p = 0.017), but not age at diagnosis. In relapsed borderline PTs, we did not find deaths due to disease progression. Patients with DM were all malignant PTs, with disease‐progression occurring within 3 years in more than 80% of patients. Among salvage treatments, the combination of antiangiogenic drugs improved the prognosis to some extent, with a significant increase in mPFS (2.77 vs. 1.53 months), but no significant statistical results were obtained (p = 0.168). Lactate dehydrogenase (LDH) was an independent predictor of the prognosis for malignant PTs (p = 0.001, HR = 1.203, 95%CI, 1.082–1.336).Conclusion: Borderline PTs rarely metastasize, and even if LR occurs, surgical resection can lead to long‐term survival. In metastatic phyllodes tumors (MPT), systemic therapy is not effective, but antiangiogenic drugs may prolong survival. LDH is an independent prognostic factor for malignant PTs to identify high‐risk tumors.

1 January 2023 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
WWWei Wang
Wei Wang
JWJiayi Wu
Jiayi Wu
KCKeyu Chen
Keyu Chen
XWXiaojia Wang
Xiaojia Wang
XSXiying Shao
Xiying Shao
Recent studies have demonstrated that the combination of Cyclin-Dependent Kinase 4/6 Inhibitor (CDK4/6i) and endocrine therapy (ET) is more effective than ET alone and significantly improves progression-free survival (PFS) and overall survival (OS) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) breast cancer (BC). Palbociclib is the first CDK4/6i approved for use, and its clinical advantages have been shown. However, 30% of patients will continue to develop secondary drug resistance. Therefore, exploring the parameters that can predict the efficacy of Palbociclib and developing a clinical prediction model is essential for evaluating the prognosis of patients.

15 September 2022 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
KCKeyu Chen
Keyu Chen
JWJiayi Wu
Jiayi Wu
ZFZiru Fang
Ziru Fang
XSXiying Shao
Xiying Shao
XWXiaojia Wang
Xiaojia Wang
Breast cancer is a kind of malignant tumor that seriously endangers women's life and health. Once diagnosed, most patients will receive a combination of treatments to achieve a cure. However, breast cancer is a heterogeneous disease. Even with the same clinical stage and pathological features, its response to treatment and postoperative recurrence risk may still be completely different. With the advent of genomic assay, some patients with early-stage breast cancer who originally needed treatment can still achieve long-term disease-free survival without adjuvant chemotherapy, so as to achieve personalized and accurate treatment mode to a certain extent. In this paper, we reviewed the 5 most widely used and studied genomic panel technologies in breast cancer, namely Oncotype DX, MammaPrint, RecurIndex, PAM50, and EndoPredict, according to accessibility and availability. Based on the results of the completed or ongoing clinical studies, we summarized the origin, applicable population, and clinical efficacy of each detection method, and discussed the potential development prospect of detection technology in the future.

7 January 2026 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
KCKeyu Chen
Keyu Chen
YXYufen Xu
Yufen Xu
BSBinbin Song
Binbin Song
YGYuyang Gu
Yuyang Gu
XXXiaofang Xu
Xiaofang Xu
MFMeiyu Fang
Meiyu Fang
Background: Li‐Fraumeni syndrome is a rare autosomal dominant disorder caused by a pathogenic mutation of the tumor suppressor gene TP53 . This disease starts at an early age and has been shown to be associated with multiple tumors. The study aims to discuss the clinical and genetic characteristics of Li‐Fraumeni syndrome (LFS) and to provide therapeutic experience of LFS. Materials and Methods: We conducted a retrospective analysis of the clinicopathologic features, family history, treatment and follow‐up in five LFS patients with germline TP53 (NCBI Gene: 7157 , HGNC: 11998 , OMIM: 191170 ) pathogenic/likely pathogenic (P/LP) variants. This research had been approved by the ethics committee and implemented. Results: Our study involved five LFS patients with germline TP53 P/LP variants, including thyroid cancer, ovarian melanoma, colon cancer, fibrosarcoma, and lung cancer. Among this group of patients, the age at which tumors first appeared was between 24 and 53 years old. Three patients had a family history of tumors, and the other two were probands in the family. Traditional chemotherapy has limited effectiveness in clinical practice and may increase the risk of tumor development. However, immune checkpoint inhibitors (ICIs) have shown unexpected efficacy in patients with high programmed cell death ligand‐1 (PD‐L1) expression. Next‐generation sequencing (NGS) and PD‐L1 detection may provide more potential targets for LFS patients to achieve better therapeutic outcomes. In addition, we have added a new TP53 frameshift mutation spectrum, namely c.642_643delTA (p.H214Qfs*7), which belongs to the pathogenic variant. This mutant has not been described in the existing literature. Conclusion: Patients with LFS may be potential beneficiaries of immune checkpoint inhibitors and targeted therapies.